Research Article - Biomedical Research (2018) Volume 29, Issue 4
XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy
Background: Some previous studies suggested that XRCC1 rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy. However, the results were not coincident. Thus, we conducted this meta-analysis.
Methods: The databases of PubMed, Embase, Cochrane Library, and Web of Science were searched. This meta-analysis was performed using Stata version 12.0 (StataCorp LP, TX, USA).
Results: In this meta-analysis study, a total of 13 relevant articles with 2540 NSCLC patients were enrolled. Results of this meta-analysis study showed that the NSCLC patients with XRCC1 rs1799782 Trp/Trp genotype were associated with worse ORR (OR=1.37; 95%CI, 1.01-1.79). In addition, XRCC1 rs1799782 Arg/Trp genotype was associated with worse ORR (OR=1.41; 95%CI, 1.14-1.75). Furthermore, NSCLC patients with XRCC1 rs1799782 Trp/Trp or Arg/Trp genotype also showed worse ORR (OR=1.39; 95%CI, 1.02-1.76).
Conclusions: In conclusion, this meta-analysis suggested that XRCC1 rs1799782 polymorphism was significantly associated with ORR in NSCLC patients treated with platinum-based chemotherapy.Author(s): Peng-Cheng Wang, Xing Du, Yi Wang, Xiao-Li Zheng